Demographic characteristics of participants in the study at baseline and at 21 months.
scabies
SCABIES
MDA–mass drug administrationThere was no significant change in scabies prevalence in either arm at the 21-month survey, compared to baseline. In Arm 1, prevalence was 17·2% (95% CI 15·7–18·7) at baseline and 18·7% (95% CI 16·8–20·6) at 21 months. In Arm 2, prevalence was 13·2% (95% CI 12·0–14·5) at baseline and 13·4% (95% CI 11·8–15·1) at 21 months. The difference between the two arms in the mean changes in scabies prevalence from baseline to 21 months was 0·8% (95% CI -9·3–11·0).There was a lower scabies prevalence in participants at 21 months who were recruited at baseline compared to those who had not (